Author： Doggrell Sheila A
Publisher： Informa Healthcare
ISSN： 1354-3784
Source： Expert Opinion on Investigational Drugs, Vol.14, Iss.1, 2005-01, pp. : 89-91
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
The BCR-ABL tyrosine kinase inhibitor imatinib has greatly improved the outcome for patients with chronic myeloid leukaemia (CML). Unfortunately, mutations causing resistance to imatinib are leading to relapses in some patients. In addition to inhibiting the wild-type BCR-ABL, BMS-354825 inhibited 14 of 15 BCR-ABL mutants. BMS-354825 treatment of immunodeficient mice prevented the progression of the disease in mice treated with the most clinical common imatinib-resistant mutant Met351Thr. The safety and efficacy of BMS-354825 is presently being evaluated in a phase I/II clinical trial in CML patients with imatinib resistance. The frequency of clinical use of BMS-3548125 in CML patients will depend on its efficacy/safety profile in clinical trial.
Related content
Access to resources
Recommend
Imatinib mesylate in the treatment of chronic myeloid leukaemia
Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 6, 2003-06 ,pp. :
Imatinib: A Review of its Use in Chronic Myeloid Leukaemia
By Moen Marit D. McKeage Kate Plosker Greg L. Siddiqui M. Asif A.
Drugs, Vol. 67, Iss. 2, 2007-01 ,pp. :